Advanced Search

Show simple item record

dc.contributor.authorToprak, Ömer
dc.contributor.authorKurt, Hüseyin
dc.contributor.authorSarı, Yasin
dc.contributor.authorŞarkış, Cihat
dc.contributor.authorUs, Halil
dc.contributor.authorKırık, Ali
dc.date.accessioned2019-10-07T06:04:50Z
dc.date.available2019-10-07T06:04:50Z
dc.date.issued2017en_US
dc.identifier.issn1420-4096
dc.identifier.issn1423-0143
dc.identifier.urihttps://doi.org/10.1159/000468530
dc.identifier.urihttps://hdl.handle.net/20.500.12462/6701
dc.descriptionToprak, Ömer (Balikesir Author)en_US
dc.description.abstractBackground/Aims: Magnesium is an essential mineral for many metabolic functions. There is very little information on the effect of magnesium supplementation on metabolic profiles of chronic kidney disease (CKD) patients. The aim of this study was to assess the influence of magnesium supplementation on metabolic profiles of pre-diabetic, obese and mild-tomoderate CKD patients with hypomagnesemia. Methods: A total of 128 hypomagnesemic, pre-diabetic and obese patients with an estimated glomerular filtration rate between 90 and 30 ml/min/1.73m(2) were enrolled in a randomised, double-blind, placebo-controlled trial. Patients in the magnesium group received 365 mg of oral magnesium (n = 57) once daily for 3 months, while patients in the control group received a placebo (n = 61), also once daily for 3 months. Hypomagnesemia is defined by a serum magnesium level <1.8 mg/dl in males and <1.9 mg/dl in females; obesity is defined as a body mass index >= 30 kg/m(2); and pre-diabetes is defined as fasting plasma glucose >= 100 but < 126 mg/dl. The primary end point of the study was the change in insulin resistance measured by the homeostastic model assessment for insulin resistance (HOMA-IR). Results: At the end of follow-up, insulin resistance (-24.5 vs. -8.2%, P = 0.007), HOMA-IR index (-31.9 vs. -3.3%, P < 0.001), hemoglobin A1c (-6.6 vs. -0.16%, P < 0.001), insulin (-29.6 vs. -2.66%, P < 0.001), waist circumference (-4.8 vs. 0.55%, P < 0.001) and uric acid (-0.8 vs. 2.2%, P = 0.004) were significantly decreased in terms of mean changes; albumin (0.91 vs. -2.91%, P = 0.007) and magnesium (0.21 +/- 0.18 vs. -0.04 +/- 0.05 mg/dl, P < 0.001) were significantly increased in those taking magnesium compared with a placebo. The decrease in metabolic syndrome (-10.5 vs. -4.9%, P = 0.183), obesity (-15.7 vs. -8.2%, P = 0.131), pre-diabetes (-17.5 vs. -9.8%, P = 0.140), and systolic (-5.0 +/- 14.8 vs. 0.22 +/- 14.9 mm Hg, P = 0.053) and diastolic (-3.07 +/- 9.7 vs. 0.07 +/- 9.6 mm Hg, P = 0.071) blood pressure did not achieve to a significant level after study. Conclusion: Our data support the argument that magnesium supplementation improves the metabolic status in hypomagnesemic CKD patients with pre-diabetes and obesity. (C) 2017 The Author(s) Published by S. Karger AG, Baselen_US
dc.language.isoengen_US
dc.publisherKargeren_US
dc.relation.isversionof10.1159/000468530en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic Kidney Diseaseen_US
dc.subjectHypomagnesemiaen_US
dc.subjectObesityen_US
dc.subjectInsulin Resistanceen_US
dc.subjectPre-Diabetesen_US
dc.titleMagnesium replacement ımproves the metabolic profile in obese and pre-diabetic patients with mild-to-moderate chronic kidney disease: a 3-month, randomised, double-blind, placebo-controlled studyen_US
dc.typearticleen_US
dc.relation.journalKidney & Blood Pressure Researchen_US
dc.contributor.departmentTıp Fakültesien_US
dc.contributor.authorID0000-0002-2865-1687en_US
dc.identifier.volume42en_US
dc.identifier.issue1en_US
dc.identifier.startpage33en_US
dc.identifier.endpage42en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record